|
1
|
Caldwell S and Park SH: The epidemiology
of hepatocellular cancer: From the perspectives of public health
problem to tumor biology. J Gastroenterol. 44(Suppl 19): 96–101.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bertino G, Di Carlo I, Ardiri A, Calvagno
GS, Demma S, Malaguarnera G, Bertino N and Malaguarnera M, Toro A
and Malaguarnera M: Systemic therapies in hepatocellular carcinoma:
Present and future. Future Oncol. 9:1533–1548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
El-Serag HB: Hepatocellular carcinoma. N
Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tomasetto C, Moog-Lutz C, Régnier CH,
Schreiber V, Basset P and Rio MC: Lasp-1 (MLN 50) defines a new LIM
protein subfamily characterized by the association of LIM and SH3
domains. FEBS Lett. 373:245–249. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schreiber V, Moog-Lutz C, Régnier CH,
Chenard MP, Boeuf H, Vonesch JL, Tomasetto C and Rio MC: Lasp-1, a
novel type of actin-binding protein accumulating in cell membrane
extensions. Mol Med. 4:675–687. 1998.PubMed/NCBI
|
|
6
|
Chew CS, Chen X, Parente JA Jr, Tarrer S,
Okamoto C and Qin HY: Lasp-1 binds to non-muscle F-actin in vitro
and is localized within multiple sites of dynamic actin assembly in
vivo. J Cell Sci. 115:4787–4799. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin YH, Park ZY, Lin D, Brahmbhatt AA, Rio
MC, Yates JR III and Klemke RL: Regulation of cell migration and
survival by focal adhesion targeting of Lasp-1. J Cell Biol.
165:421–432. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stölting M, Wiesner C, van Vliet V, Butt
E, Pavenstädt H, Linder S and Kremerskothen J: Lasp-1 regulates
podosome function. PLoS One. 7:e353402012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grunewald TG, Kammerer U, Winkler C,
Schindler D, Sickmann A, Honig A and Butt E: Overexpression of
LASP-1 mediates migration and proliferation of human ovarian cancer
cells and influences zyxin localisation. Br J Cancer. 96:296–305.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Traenka C, Remke M, Korshunov A, et al:
Role of LIM and SH3 protein 1 (LASP1) in the metastatic
dissemination of medulloblastoma. Cancer Res. 70:8003–8014. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Payton S: Bladder cancer: LASP-1 - a
promising urine marker for detection of bladder cancer. Nat Rev
Urol. 9:2402012. View Article : Google Scholar
|
|
12
|
Wang H, Li W, Jin X, Cui S and Zhao L: LIM
and SH3 protein 1, a promoter of cell proliferation and migration,
is a novel independent prognostic indicator in hepatocellular
carcinoma. Eur J Cancer. 49:974–983. 2013. View Article : Google Scholar
|
|
13
|
Shimizu F, Shiiba M, Ogawara K, et al:
Overexpression of LIM and SH3 protein 1 leading to accelerated G2/M
phase transition contributes to enhanced tumourigenesis in oral
cancer. PLoS One. 8:e831872013. View Article : Google Scholar
|
|
14
|
Hailer A, Grunewald TGP, Orth M, Reiss C,
Kneitz B, Spahn M and Butt E: Loss of tumor suppressor mir-203
mediates overexpression of LIM and SH3 protein 1 (LASP1) in
high-risk prostate cancer thereby increasing cell proliferation and
migration. Oncotarget. 5:4144–4153. 2014.PubMed/NCBI
|
|
15
|
Grunewald TG, Kammerer U, Schulze E,
Schindler D, Honig A, Zimmer M and Butt E: Silencing of LASP-1
influences zyxin localization, inhibits proliferation and reduces
migration in breast cancer cells. Exp Cell Res. 312:974–982. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao L, Wang H, Liu C, et al: Promotion of
colorectal cancer growth and metastasis by the LIM and SH3 domain
protein 1. Gut. 59:1226–1235. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Grunewald TG, Kammerer U, Kapp M, Eck M,
Dietl J, Butt E and Honig A: Nuclear localization and cytosolic
overexpression of LASP-1 correlates with tumor size and
nodal-positivity of human breast carcinoma. BMC Cancer. 7:198–207.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Frietsch JJ, Grunewald TG, Jasper S,
Kammerer U, Herterich S, Kapp M, Honig A and Butt E: Nuclear
localisation of LASP-1 correlates with poor long-term survival in
female breast cancer. Br J Cancer. 102:1645–1653. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mihlan S, Reiß C, Thalheimer P, Herterich
S, Gaetzner S, Kremerskothen J, Pavenstädt HJ, Lewandrowski U,
Sickmann A and Butt E: Nuclear import of LASP-1 is regulated by
phosphorylation and dynamic protein-protein interactions. Oncogene.
32:2107–2113. 2013. View Article : Google Scholar
|
|
20
|
Salvi A, Bongarzone I, Miccichè F, Arici
B, Barlati S and De Petro G: Proteomic identification of LASP-1
down-regulation after RNAi urokinase silencing in human
hepatocellular carcinoma cells. Neoplasia. 11:207–219.
2009.PubMed/NCBI
|
|
21
|
Grunewald TG and Butt E: The LIM and SH3
domain protein family: Structural proteins or signal transducers or
both? Mol Cancer. 7:31–42. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Neo SY, Leow CK, Vega VB, Long PM, Islam
AFM, Lai PB, Liu ET and Ren EC: Identification of discriminators of
hepatoma by gene expression profiling using a minimal dataset
approach. Hepatology. 39:944–953. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang B, Feng P, Xiao Z and Ren EC: LIM and
SH3 protein 1 (Lasp1) is a novel p53 transcriptional target
involved in hepatocellular carcinoma. J Hepatol. 50:528–537. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang R, Kong F, Hu L, You H, Zhang P, Du W
and Zheng K: Role of hepatitis B virus X protein in regulating LIM
and SH3 protein 1 (LASP-1) expression to mediate proliferation and
migration of hepatoma cells. Virol J. 9:163–175. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
De Petro G, Tavian D, Copeta A, Portolani
N, Giulini SM and Barlati S: Expression of urokinase-type
plasminogen activator (u-PA), u-PA receptor, and tissue-type PA
messenger RNAs in human hepatocellular carcinoma. Cancer Res.
58:2234–2239. 1998.PubMed/NCBI
|
|
26
|
Yeh YT, Chang CW, Wei RJ and Wang SN:
Progesterone and related compounds in hepatocellular carcinoma:
Basic and clinical aspects. Biomed Res Int. 2013:2905752013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yeh SH and Chen PJ: Gender disparity of
hepatocellular carcinoma: The roles of sex hormones. Oncology.
78(Suppl 1): 172–179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li Z, Tuteja G, Schug J and Kaestner KH:
Foxa1 and Foxa2 are essential for sexual dimorphism in liver
cancer. Cell. 148:72–83. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rosenbloom KR, Dreszer TR, Long JC, et al:
ENCODE whole-genome data in the UCSC Genome Browser: Update 2012.
Nucleic Acids Res. 40:D912–D917. 2012. View Article : Google Scholar :
|
|
30
|
Ivaska J, Pallari HM, Nevo J and Eriksson
JE: Novel functions of vimentin in cell adhesion, migration, and
signaling. Exp Cell Res. 313:2050–2062. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Savagner P: The epithelial-mesenchymal
transition (EMT) phenomenon. Ann Oncol. 21(Suppl 7): vii89–vii92.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hu L, Lau SH, Tzang CH, et al: Association
of vimentin overexpression and hepatocellular carcinoma metastasis.
Oncogene. 23:298–302. 2004.
|
|
33
|
Pan TL, Wang PW, Huang CC, Yeh CT, Hu TH
and Yu JS: Network analysis and proteomic identification of
vimentin as a key regulator associated with invasion and metastasis
in human hepatocellular carcinoma cells. J Proteomics.
75:4676–4692. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang H, Shi J, Luo Y, Liao Q, Niu Y, Zhang
F, Shao Z, Ding Y and Zhao L: LIM and SH3 protein 1 induces
TGFβ-mediated epithelial-mesenchymal transition in human colorectal
cancer by regulating S100A4 expression. Clin Cancer Res.
20:5835–5847. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Salvi A, Arici B, Alghisi A, Barlati S and
De Petro G: RNA interference against urokinase in hepatocellular
carcinoma xenografts in nude mice. Tumour Biol. 28:16–26. 2007.
View Article : Google Scholar
|
|
36
|
Salvi A, Arici B, De Petro G and Barlati
S: Small interfering RNA urokinase silencing inhibits invasion and
migration of human hepatocellular carcinoma cells. Mol Cancer Ther.
3:671–678. 2004.PubMed/NCBI
|
|
37
|
Salvi A, Abeni E, Portolani N, Barlati S
and De Petro G: Human hepatocellular carcinoma cell-specific miRNAs
reveal the differential expression of miR-24 and miR-27a in
cirrhotic/non-cirrhotic HCC. Int J Oncol. 42:391–402. 2013.
|
|
38
|
Wu KJ, Zeng J, Zhu GD, Zhang LL, Zhang D,
Li L, Fan JH, Wang XY and He DL: Silibinin inhibits prostate cancer
invasion, motility and migration by suppressing vimentin and MMP-2
expression. Acta Pharmacol Sin. 30:1162–1168. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Satelli A and Li S: Vimentin in cancer and
its potential as a molecular target for cancer therapy. Cell Mol
Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Salvi A, Conde I, Abeni E, Arici B, Grossi
I, Specchia C, Portolani N, Barlati S and De Petro G: Effects of
miR-193a and sorafenib on hepatocellular carcinoma cells. Mol
Cancer. 12:162–176. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Salvi A, Sabelli C, Moncini S, Venturin M,
Arici B, Riva P, Portolani N, Giulini SM, De Petro G and Barlati S:
MicroRNA-23b mediates urokinase and c-met downmodulation and a
decreased migration of human hepatocellular carcinoma cells. FEBS
J. 276:2966–2982. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gorla L, Mondellini P, Cuccuru G, Miccichè
F, Cassinelli G, Cremona M, Pierotti MA, Lanzi C and Bongarzone I:
Proteomics study of medullary thyroid carcinomas expressing RET
germ-line mutations: Identification of new signaling elements. Mol
Carcinog. 48:220–231. 2009. View Article : Google Scholar
|
